Objectives. Romania has faced a re-emergence of sylvatic rabies since 2020, in contrast with the significant decline in cases seen across much of the EU. Objectives were: a) to get updated information on rabies situation in the country during the year 2025, b) to sequence the Babeș strain of fixed rabies virus and to compare it with the cell culture-adapted variant (BAB-TMP) and other vaccine strains, c) to present the innovative approach for development of immunoprophylaxis and therapy according to National and EUProgramme.
Materials and methods. Existing data on confirmed rabies cases in animals during 2025 were centralized within IDAH Bucharest. For sequencing of the Babeș strain, the MiSeq platform was used, and data were processed using public databases. Other information were obtained from recent reports and scientific literature.
Results and discussion. In 2025 (by October), 53 cases of rabies in animals were confirmed, almost exclusively in the counties bordering Ukraine. One fatal human case was also confirmed. Surprisingly, the fixed rabies virus Babes is genetically stable, with only five mutations identified in the two variants of the strain, of which 3 in the G gene and two in the L gene. The proteome identity with the established vaccine strains was 93-94%. Exploring new recombinant vaccine variants (e.g. G glycoprotein) for potential use in animals and humans, and investigating new antiviral agents like new monoclonal antibody cocktails, are new fields of exploration in the area.
Conclusions. Integrated strategies by emphasizing the "One Health" approach, coordinating mass vaccination of animal populations with public awareness campaigns and robust surveillance systems plus using innovative approaches in immunoprophylaxis for human health will likely lead towards global elimination goals of rabies ("Zero by 30").
Funding source: This work was carried out in the Project PSCD - VIROMAB H, financed by the Romanian Ministry of National Defence.
Obiective. România se confruntă cu o re-emergență a rabiei silvatice din 2020, În contrast cu scăderea semnificativă a numărului de cazuri observată În mare parte a UE. Obiectivele au fost: a) obținerea de informații actualizate despre situația rabiei În țară În cursul anului 2025, b) secvențierea tulpinii Babeș de virus rabic fix, compararea acesteia cu varianta adaptată În culturi celulare și alte tulpini vaccinale, c) prezentarea abordării inovatoare pentru dezvoltarea imunoprofilaxiei și terapiei conform Programului Național și al UE.
Materiale și metode. Datele existente privind cazurile confirmate de rabie la animale, În cursul anului 2025, au fost centralizate În cadrul IDSA București. Pentru secvențierea tulpinii Babeș a fost utilizată platforma MiSeq. Alte informații au fost obținute din rapoarte recente și literatura științifică.
Rezultate și discuții. În 2025 (până În octombrie) au fost confirmate 53 de cazuri de rabie la animale, aproape exclusiv În județele de graniță cu Ucraina. De asemenea, a fost confirmat un caz fatal la om. În mod surprinzător, virusul rabic fix Babeș este stabil genetic, cu doar cinci mutații identificate În cele două variante ale tulpinii dintre care, 3 În gena G și două În gena L. Identitatea proteomului cu a tulpinilor vaccinale consacrate a fost de 93-94%. Explorarea de noi variante de vaccinuri recombinante (e.g. glicoproteinaG) pentru utilizare potențială la animale și om, și investigarea de noi agenți antivirali cum ar fi noile cocktail-uri de anticorpi monoclonali, reprezintă noi domenii de explorare În domeniu.
Concluzii. Strategiile integrate prin accentul pus pe abordarea „One Health", coordonarea vaccinării În masă a populațiilor de animale cu campanii de conștientizare publică și sisteme robuste de supraveghere, plus utilizarea abordărilor inovatoare În imunoprofilaxia pentru sănătatea umană, vor conduce, probabil, la atingerea obiectivelor globale de eliminare a rabiei („Zero până În 30").
Sursa de finanțare: Această lucrare a fost realizată prin proiectul PSCD - VIROMAB H, finanțat de Ministerul Apărării Naționale.
*Corresponding author: Radu-Iulian Tănasă, e-mail: [email protected]
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
© 2025. This work is published under https://www.roami.ro (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Abstract
Objectives. Romania has faced a re-emergence of sylvatic rabies since 2020, in contrast with the significant decline in cases seen across much of the EU. Objectives were: a) to get updated information on rabies situation in the country during the year 2025, b) to sequence the Babeș strain of fixed rabies virus and to compare it with the cell culture-adapted variant (BAB-TMP) and other vaccine strains, c) to present the innovative approach for development of immunoprophylaxis and therapy according to National and EUProgramme. Materials and methods. Existing data on confirmed rabies cases in animals during 2025 were centralized within IDAH Bucharest. For sequencing of the Babeș strain, the MiSeq platform was used, and data were processed using public databases. Other information were obtained from recent reports and scientific literature. Results and discussion. In 2025 (by October), 53 cases of rabies in animals were confirmed, almost exclusively in the counties bordering Ukraine. One fatal human case was also confirmed. Surprisingly, the fixed rabies virus Babes is genetically stable, with only five mutations identified in the two variants of the strain, of which 3 in the G gene and two in the L gene. The proteome identity with the established vaccine strains was 93-94%. Exploring new recombinant vaccine variants (e.g. G glycoprotein) for potential use in animals and humans, and investigating new antiviral agents like new monoclonal antibody cocktails, are new fields of exploration in the area. Conclusions. Integrated strategies by emphasizing the "One Health" approach, coordinating mass vaccination of animal populations with public awareness campaigns and robust surveillance systems plus using innovative approaches in immunoprophylaxis for human health will likely lead towards global elimination goals of rabies ("Zero by 30").





